CME czar goes to Pfizer

Share this article:
Maureen Doyle-Scharff
Maureen Doyle-Scharff
Pfizer, in the midst of revamping its CME department, scored a coup with the recent hiring of Maureen Doyle-Scharff, MBA.

Doyle-Scharff comes from the Ross Products division of Abbott Labs, where for the last two years she directed healthcare education, policy and programs. Her new title at Pfizer is director, medical education, US external medical affairs.

A well-known advocate of CME among all provider groups, Doyle-Scharff holds positions on the boards of several medical education professional groups. Before joining Ross, she was executive director, professional and strategic customer alliances for Johnson & Johnson.

Pfizer's Medical Education Grants department, under the direction of Mike Saxton, MEd, senior director, team leader, is placing more emphasis on the competency of personnel. Earlier this year, the firm made reviewers in the department re-interview for jobs, with candidates required to meet higher standards.

Bringing in someone of high stature, who shares his vision, could put Saxton in a better position to implement his plans, say people familiar with the matter.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...